CompletedNot Applicable

Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values

Bosnia and Herzegovina800 participantsStarted 2012-04

Plain-language summary

This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients, treated with one HMG-CoA reductase inhibitors for at least 6 months without changing the dose for the last 4 weeks at least * All patients must sign informed consent form Exclusion Criteria: * Patients who have not signed the Informed Consent Form * Patients with contraindication for the treatment with HMG-CoA reductase inhibitors as per SmPC approved in Bosnia and Herzegovina

What they're measuring

The number and percentage of patients reaching the LDL-C goals, according to the Fourth Joint European Task Force guideline.

Timeframe: During the study visit scheduled at least 6 months after HMG-CoA reductase inhibitor has been initiated

Trial details

NCT IDNCT01483950

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2013-01

View on ClinicalTrials.gov More Hypercholesterolaemia trials